Treatment of Carcinoid of Small Intestine in Advanced Unresectable Neuroendocrine Tumour, Somatostatin Receptor Positive

This protocol defines the first-line systemic approach for patients with advanced, unresectable small intestine neuroendocrine tumour that is somatostatin receptor positive — a clinically important subgroup with a specific preferred treatment strategy.

Clinical Scenario

Advanced unresectable small intestine neuroendocrine tumour (Si-NET), grade 1 or grade 2, confirmed somatostatin receptor positive, without carcinoid syndrome. Systemic therapy is indicated as first-line management.

First-Line Approach (partial overview)

In this setting, the preferred first-line systemic treatment is a long-acting somatostatin analogue. The specific agent, dosing parameters, and sequencing for subsequent lines are detailed in the full structured protocol.

Complete regimen — including agent selection, follow-on lines, and monitoring — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jne.13423

In the presence of advanced unresectable Si-NET G1 or G2 long-acting SSA (either lanreotide or octreotide) is the preferred first-line treatment (RECOMMENDATION A-1b).

It is therefore widely accepted that SSA (either lanreotide autogel [AG] or octreotide long acting release [LAR]) is the preferred first-line treatment in the presence of advanced G1 or G2 (especially if Ki-67 below 10%) Si-NET suitable for systemic therapy.

View source ↗